** Brokerage Stifel raises PT on drugmaker Alnylam Pharmaceuticals' ALNY.O to $345 from $300 following expanded U.S. approval for its heart disease drug
** The new PT represents a 28.5% upside to the stock's last close
** Brokerage believes ALNY's drug Amvuttra will be a "go-to therapy" for patients with heart disease condition who progress on a stabilizer
** Amvuttra, a quarterly injection, was cleared to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart and potentially causing organ to fail
** Stifel says physician feedback on the drug has been broadly favorable
** Twenty four of 31 brokerages rate the stock "buy" or higher, 7 "hold"; their median PT is $316.71, according to data compiled by LSEG
** As of last close, ALNY has risen 80% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。